{
  "id": "41134222",
  "source": "MED",
  "pmid": "41134222",
  "doi": "10.1080/13696998.2025.2579407",
  "title": "Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review.",
  "authorString": "Mugwagwa T, Marcano Belisario J, Hartley L, Phan NTN.",
  "authorList": {
    "author": [
      {
        "fullName": "Mugwagwa T",
        "firstName": "Tendai",
        "lastName": "Mugwagwa",
        "initials": "T",
        "authorId": {
          "type": "ORCID",
          "value": "0000-0001-7515-8548"
        },
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "Global Access and Value, Pfizer Ltd, Tadworth, UK."
            }
          ]
        }
      },
      {
        "fullName": "Marcano Belisario J",
        "firstName": "Jos\u00e9",
        "lastName": "Marcano Belisario",
        "initials": "J",
        "authorId": {
          "type": "ORCID",
          "value": "0000-0002-3372-2996"
        },
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "RTI Health Solutions, Manchester, UK."
            }
          ]
        }
      },
      {
        "fullName": "Hartley L",
        "firstName": "Louise",
        "lastName": "Hartley",
        "initials": "L",
        "authorId": {
          "type": "ORCID",
          "value": "0000-0001-5251-2321"
        },
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "RTI Health Solutions, Manchester, UK."
            }
          ]
        }
      },
      {
        "fullName": "Phan NTN",
        "firstName": "Nguyen Thi Nhan",
        "lastName": "Phan",
        "initials": "NTN",
        "authorId": {
          "type": "ORCID",
          "value": "0000-0002-3603-1736"
        },
        "authorAffiliationDetailsList": {
          "authorAffiliation": [
            {
              "affiliation": "RTI Health Solutions, Manchester, UK."
            }
          ]
        }
      }
    ]
  },
  "authorIdList": {
    "authorId": [
      {
        "type": "ORCID",
        "value": "0000-0001-5251-2321"
      },
      {
        "type": "ORCID",
        "value": "0000-0001-7515-8548"
      },
      {
        "type": "ORCID",
        "value": "0000-0002-3372-2996"
      },
      {
        "type": "ORCID",
        "value": "0000-0002-3603-1736"
      }
    ]
  },
  "dataLinksTagsList": {
    "dataLinkstag": [
      "altmetrics"
    ]
  },
  "journalInfo": {
    "issue": "1",
    "volume": "28",
    "journalIssueId": 3867857,
    "dateOfPublication": "2025 Dec",
    "monthOfPublication": 12,
    "yearOfPublication": 2025,
    "printPublicationDate": "2025-12-01",
    "journal": {
      "title": "Journal of medical economics",
      "medlineAbbreviation": "J Med Econ",
      "issn": "1369-6998",
      "isoabbreviation": "J Med Econ",
      "essn": "1941-837X",
      "nlmid": "9892255"
    }
  },
  "pubYear": "2025",
  "pageInfo": "1933-1954",
  "abstractText": "<h4>Aims</h4>Nirmatrelvir/ritonavir (NMV/r) is an antiviral drug used to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in patients at high risk of progression to severe COVID-19. We conducted an economic systematic literature review to assess key parameters, structures, and outcomes of existing models and analyses of the economic value of NMV/r treatment.<h4>Methods</h4>A systematic search of Embase, MEDLINE, and MEDLINE In-Process, as well as bibliographies of systematic reviews and conference and health technology assessment websites, identified relevant articles published between 2022 and 2024. A quality assessment was conducted for each economic evaluation using the Drummond checklist.<h4>Results</h4>Of the 22 included economic evaluations, most were cost-utility analyses (<i>n</i>\u2009=\u200910) and cost-effectiveness analyses (<i>n</i>\u2009=\u20099). Most used a short-term decision tree with a long-term Markov model (<i>n</i>\u2009=\u20095), with time horizons between 28\u2009days to a lifetime, and were from a healthcare system perspective (<i>n</i>\u2009=\u20097). Most conducted scenario analyses (<i>n</i>\u2009=\u200915) and/or sensitivity analyses (<i>n</i>\u2009=\u200918), and many based treatment effectiveness estimates on the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) randomized controlled trial (<i>n</i>\u2009=\u20097). Overall, NMV/r showed economic value across different willingness-to-pay thresholds when compared with standard of care or best supportive care, and all economic evaluations were high or moderate quality.<h4>Limitations</h4>Most included economic evaluations were from high-income countries and all were written in English and may not be generalizable to low-income countries or healthcare systems.<h4>Conclusion</h4>While economic evaluations were heterogeneous in terms of modeling approach, population, treatments, and context, these findings indicate that NMV/r has economic value for patients with mild-to-moderate COVID-19 with a high risk of progression to severe disease. Significant changes to the burden of COVID-19 due to the evolution of COVID-19 variants and new vaccination strategies, may warrant updates models.",
  "affiliation": "Global Access and Value, Pfizer Ltd, Tadworth, UK.",
  "publicationStatus": "ppublish",
  "language": "eng",
  "pubModel": "Print-Electronic",
  "pubTypeList": {
    "pubType": [
      "Systematic Review",
      "Journal Article"
    ]
  },
  "grantsList": {
    "grant": [
      {
        "agency": "Pfizer",
        "orderIn": 0
      }
    ]
  },
  "meshHeadingList": {
    "meshHeading": [
      {
        "majorTopic_YN": "N",
        "descriptorName": "Humans"
      },
      {
        "majorTopic_YN": "Y",
        "descriptorName": "Ritonavir",
        "meshQualifierList": {
          "meshQualifier": [
            {
              "abbreviation": "EC",
              "qualifierName": "economics",
              "majorTopic_YN": "N"
            },
            {
              "abbreviation": "TU",
              "qualifierName": "therapeutic use",
              "majorTopic_YN": "N"
            }
          ]
        }
      },
      {
        "majorTopic_YN": "N",
        "descriptorName": "Drug Combinations"
      },
      {
        "majorTopic_YN": "Y",
        "descriptorName": "Antiviral Agents",
        "meshQualifierList": {
          "meshQualifier": [
            {
              "abbreviation": "EC",
              "qualifierName": "economics",
              "majorTopic_YN": "N"
            },
            {
              "abbreviation": "TU",
              "qualifierName": "therapeutic use",
              "majorTopic_YN": "N"
            }
          ]
        }
      },
      {
        "majorTopic_YN": "N",
        "descriptorName": "Cost-Benefit Analysis"
      },
      {
        "majorTopic_YN": "N",
        "descriptorName": "COVID-19"
      },
      {
        "majorTopic_YN": "N",
        "descriptorName": "SARS-CoV-2"
      },
      {
        "majorTopic_YN": "Y",
        "descriptorName": "COVID-19 Drug Treatment"
      }
    ]
  },
  "keywordList": {
    "keyword": [
      "Economic evaluation",
      "Cost-effectiveness",
      "Economic Models",
      "I10",
      "Covid-19",
      "P00",
      "F00",
      "Nirmatrelvir/ritonavir",
      "Nmv/r",
      "Paxlovid"
    ]
  },
  "chemicalList": {
    "chemical": [
      {
        "name": "Antiviral Agents",
        "registryNumber": "0"
      },
      {
        "name": "Drug Combinations",
        "registryNumber": "0"
      },
      {
        "name": "Ritonavir",
        "registryNumber": "O3J8G9O825"
      }
    ]
  },
  "subsetList": {
    "subset": [
      {
        "code": "IM",
        "name": "Index Medicus"
      }
    ]
  },
  "fullTextUrlList": {
    "fullTextUrl": [
      {
        "availability": "Subscription required",
        "availabilityCode": "S",
        "documentStyle": "doi",
        "site": "DOI",
        "url": "https://doi.org/10.1080/13696998.2025.2579407"
      }
    ]
  },
  "isOpenAccess": "N",
  "inEPMC": "N",
  "inPMC": "N",
  "hasPDF": "N",
  "hasBook": "N",
  "hasSuppl": "N",
  "citedByCount": 0,
  "hasData": "N",
  "hasReferences": "Y",
  "hasTextMinedTerms": "Y",
  "hasDbCrossReferences": "N",
  "hasLabsLinks": "Y",
  "license": "cc by-nc-nd",
  "hasEvaluations": "N",
  "authMan": "N",
  "epmcAuthMan": "N",
  "nihAuthMan": "N",
  "hasTMAccessionNumbers": "N",
  "dateOfCompletion": "2025-11-06",
  "dateOfCreation": "2025-10-24",
  "firstIndexDate": "2025-10-24",
  "dateOfRevision": "2025-11-06",
  "electronicPublicationDate": "2025-11-06",
  "firstPublicationDate": "2025-11-06"
}